|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||40.14 - 40.14|
|52 Week Range||32.77 - 43.83|
|PE Ratio (TTM)||16.34|
|Forward Dividend & Yield||0.63 (1.52%)|
|1y Target Est||N/A|
Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application (NDA) in the course of 2018. Nasal administration could provide significant value to patients who currently have limited treatment options.
Investors pursuing a solid, dependable stock investment can often be led to UCB SA (ENXTBR:UCB), a large-cap worth €12.49B. One reason being its ‘too big to fail’ aura which givesRead More...
UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina (USA). At the core of the Element Genomics platform is a suite of technologies to improve understanding of genome structure and function such as CRISPR editing technologies used for genomic and epigenomic regulatory region analysis and modulation, underpinned and enabled with advanced informatics capabilities, and driven by a strong scientific team. Element Genomics' proven technologies and expertise will enhance UCB's scientific research platform enabling the company to continue to enrich its pipeline, in particular strengthening target discovery and characterization in disease relevant systems.
When UCB SA’s (ENXTBR:UCB) announced its latest earnings (31 December 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks I used wereRead More...
UCB SA (ENXTBR:UCB) received a lot of attention from a substantial price movement on the ENXTBR in the over the last few months, increasing to €71.12 at one point, andRead More...
BRUSSELS , March 22, 2018 /PRNewswire/ -- U.S. Food and Drug Administration (FDA) approves label change for UCB's CIMZIA ® (certolizumab pegol) Data added to the label includes first-of-their-kind pharmacokinetic ...
"UCB is thrilled to participate in the important scientific exchange at AAD this week and to translate our learnings into improved patient care. "As our research at AAD shows, UCB is executing on its Patient Value Strategy to connect the unmet needs of patients with innovative science.
THOUSAND OAKS, Calif. and BRUSSELS, Jan. 7, 2018 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for EVENITY™* (romosozumab) for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. If approved in Europe, EVENITY will be a novel osteoporosis treatment that increases bone formation and reduces bone resorption simultaneously to increase bone mineral density (BMD) and reduce the risk of fracture.
BRUSSELS , Nov. 6, 2017 /PRNewswire/ -- Key data focus on inflammatory and osteoporosis in patient populations with unmet needs including women of childbearing age and others: The results from the first-of-its-kind ...
ATLANTA and BRUSSELS , Nov. 6, 2017 /PRNewswire/ -- VIMPAT® (lacosamide) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset ...
Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes
-- New indication comes just 18 months after launch of BRIVIACT® in the U.S. This is a new indication for BRIVIACT, which is already approved in the U.S. as adjunctive treatment for POS in patients in this age group.
THOUSAND OAKS, Calif. and BRUSSELS, Sept. 11, 2017 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced detailed results from the Phase 3 ARCH study showing that 12 months of EVENITY™* (romosozumab) followed by alendronate was superior in reducing new vertebral, clinical, non-vertebral and hip fracture risk in postmenopausal women with osteoporosis at high risk for fracture, compared to alendronate alone. Overall adverse events and serious adverse events were generally similar between the treatment groups with the exception of the previously reported imbalance in positively adjudicated cardiovascular serious adverse events.
THOUSAND OAKS, Calif. and BRUSSELS, July 16, 2017 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologics License Application (BLA) for EVENITY™* (romosozumab) as a treatment for postmenopausal women with osteoporosis. The original submission included data from the pivotal Phase 3 placebo-controlled FRAME study of postmenopausal women with osteoporosis. The resubmission will also include the efficacy and safety data from the BRIDGE study, the Phase 3 trial evaluating EVENITY in men with osteoporosis, which has also been requested.
BRUSSELS, June 13, 2017 /PRNewswire/ -- UCB today presented results from CRIB, a pharmacokinetic study designed to assess if CIMZIA® (certolizumab pegol) is transferred across the placenta from pregnant women to their infants. The study used a sensitive immunoassay designed specifically to measure CIMZIA and found no measurable levels in 13 out of 14 infant blood samples at birth, and in all infant samples at weeks four and eight after birth.
UCB stock plummeted Monday after clinical trials shone a light over a possible safety risk related to the Osteoporosis treatment that it has been developing alongside Amgen
THOUSAND OAKS, Calif. and BRUSSELS, May 21, 2017 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that the EVENITY™* (romosozumab) ARCH study met both primary endpoints and the key secondary endpoint. At the primary analysis, treatment with EVENITY for 12 months followed by alendronate significantly reduced the incidence of new vertebral fractures through 24 months, clinical fractures (primary endpoints) and non-vertebral fractures (key secondary endpoint) in postmenopausal women with osteoporosis at high risk for fracture, compared to alendronate alone.
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing UCB SA with the following peers – Amgen Inc., Shire PLC Sponsored ADR, Pfizer Inc., Biogen Inc., Novartis AG Sponsored ADR and Catalyst Pharmaceuticals, Inc. (AMGN-US, SHPG-US, PFE-US, BIIB-US, NVS-US and CPRX-US). UCB SA’s dividend yield is 1.03 percent and its dividend payout is 24.00 ... Read more (Read more...)